Document Detail

Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty.
MedLine Citation:
PMID:  24685816     Owner:  NLM     Status:  Publisher    
BACKGROUND: Although primary angioplasty achieves Thrombolysis In Myocardial Infarction (TIMI) 3 flow in most patients with ST-elevation myocardial infarction, epicardial recanalization does not guarantee optimal perfusion in a large proportion of patients. Multivessel disease has been demonstrated to be associated with impaired survival, however its impact on infarct size has not been largely investigated, that therefore is the aim of the current study.
METHODS: Our population is represented by 827 STEMI patients undergoing primary PCI. Infarct size was evaluated at 30 days by technetium-99m-sestamibi.
RESULTS: Multivessel disease was observed in 343 patients (41.5%). It was associated with older age (65 [57-74] vs 63 [53-71], p < 0.001), higher rate of previous MI (6.4% vs 2.5%, p = 0.005), longer ischemia time evaluated as continuous variable (210 [155-280] min vs 196 [145-270] min, p = 0.065) or percentage of patients with ischemia time >3 h (63.7% vs 56.4%, p = 0.038), and a trend in more cardiogenic shock (5.5% vs 2.9%, p = 0.055). Patients with multivessel disease received more often Abciximab (92.1% vs 88.4%, p < 0.001), Intra-aortic balloon pump (6.4% vs 1.9%, p < 0.001). No differences were observed in other clinical or angiographic characteristics. In particular, multivessel disease did not affect the rate of postprocedural TIMI 3 flow (90.9% vs 93.4%, p = 0.18) and ST-segment resolution (52.4% vs 54.9%, p = 0.48). Multivessel disease did not affect infarct size (12.7% [4.5%-24.9%] vs 12.3% [4%-24.1%], p = 0.58). Similar results were observed in subanalyses without any significant interaction for each variable (anterior infarct location (p int = 0.23), gender (p int = 0.9), age (p int = 0.7), diabetes (p int = 0.15)). The absence of any impact of multivessel disease on infarct size was confirmed when the analysis was conducted according to the percentage of patients with infarct size above the median, even after correction for baseline characteristics, such as age, previous MI, ischemia time, use of Gp IIb-IIIa inhibitors, cardiogenic shock, ischemia time (OR [95% CI] = 1.09 [0.82-1.45], p = 0.58).
CONCLUSIONS: This study shows that among STEMI patients undergoing primary PCI multivessel disease does not affect infarct size.
Giuseppe De Luca; Guido Parodi; Roberto Sciagrà; Benedetta Bellandi; Vincenzo Comito; Ruben Vergara; Angela Migliorini; Renato Valenti; David Antoniucci
Related Documents :
16085256 - Patients with positive preoperative stress tests undergoing vascular surgery.
2458836 - After the myocardial infarction: a review and approach to risk stratification.
12644346 - The thrombolysis in myocardial infarction risk score in unstable angina/non-st-segment ...
7634446 - Infarct size after acute myocardial infarction measured by quantitative tomographic 99m...
20956396 - Right ventricular myocardial infarction: pathophysiology, diagnosis, and management.
11128796 - A complication in anticoagulation using low-molecular weight heparin in a patient with ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-12
Journal Detail:
Title:  Atherosclerosis     Volume:  234     ISSN:  1879-1484     ISO Abbreviation:  Atherosclerosis     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-4-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  244-248     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in ...
Next Document:  Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable c...